BACKGROUND: Intra-arterial therapies for acute ischemic stroke are increasingly available. Intravenous therapy (IV) followed immediately by intra-arterial therapy (IA) has been shown to be safe, but such therapy is resource intensive. Selecting the best patients for this therapy may be accomplished with the use of baseline neuroimaging. METHODS: We used data from the IMS-1 and National Institute for Neurological Disorders and Stroke tissue plasminogen activator (tPA) stroke studies to compare outcomes among IV-IA tPA, IV-tPA, and placebo treatment stratified by the baseline CT scan appearance. The CT scans were scored using the Alberta Stroke Program Early CT (ASPECT) score and dichotomized into ASPECT score > 7 (favorable scan) and ASPECT score < or = 7 (unfavorable scan). Logistic regression was used to assess for an ASPECT score by treatment interaction. RESULTS: A total of 460 patients was included. Age and sex were similar among the 3 groups. The IV-IA tPA cohort had a higher median National Institutes of Health stroke scale (NIHSS) score (18 versus 17) compared with the IV tPA cohort. The proportion of patients with favorable CT scans (ASPECT score > 7) was lowest in the IV-IA tPA group. A multiplicative interaction effect was shown indicating that patients with an ASPECT score > 7 in the IV-IA cohort were more likely to have a good outcome compared with IV tPA and with placebo. Harm may accrue to patients treated with IV-IA therapy who have an unfavorable baseline CT scan appearance. CONCLUSIONS: Patients with a favorable baseline CT scan appearance are the most likely to benefit from IV-IA therapy. This hypothesis will be tested in the IMS-3 study.
BACKGROUND: Intra-arterial therapies for acute ischemic stroke are increasingly available. Intravenous therapy (IV) followed immediately by intra-arterial therapy (IA) has been shown to be safe, but such therapy is resource intensive. Selecting the best patients for this therapy may be accomplished with the use of baseline neuroimaging. METHODS: We used data from the IMS-1 and National Institute for Neurological Disorders and Stroketissue plasminogen activator (tPA) stroke studies to compare outcomes among IV-IA tPA, IV-tPA, and placebo treatment stratified by the baseline CT scan appearance. The CT scans were scored using the Alberta Stroke Program Early CT (ASPECT) score and dichotomized into ASPECT score > 7 (favorable scan) and ASPECT score < or = 7 (unfavorable scan). Logistic regression was used to assess for an ASPECT score by treatment interaction. RESULTS: A total of 460 patients was included. Age and sex were similar among the 3 groups. The IV-IA tPA cohort had a higher median National Institutes of Health stroke scale (NIHSS) score (18 versus 17) compared with the IV tPA cohort. The proportion of patients with favorable CT scans (ASPECT score > 7) was lowest in the IV-IA tPA group. A multiplicative interaction effect was shown indicating that patients with an ASPECT score > 7 in the IV-IA cohort were more likely to have a good outcome compared with IV tPA and with placebo. Harm may accrue to patients treated with IV-IA therapy who have an unfavorable baseline CT scan appearance. CONCLUSIONS:Patients with a favorable baseline CT scan appearance are the most likely to benefit from IV-IA therapy. This hypothesis will be tested in the IMS-3 study.
Authors: A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera Journal: JAMA Date: 1999-12-01 Impact factor: 56.272
Authors: J H Pexman; P A Barber; M D Hill; R J Sevick; A M Demchuk; M E Hudon; W Y Hu; A M Buchan Journal: AJNR Am J Neuroradiol Date: 2001-09 Impact factor: 3.825
Authors: Anthony J Furlan; Dirk Eyding; Gregory W Albers; Yasir Al-Rawi; Kennedy R Lees; Howard A Rowley; Christian Sachara; Mariola Soehngen; Steven Warach; Werner Hacke Journal: Stroke Date: 2006-03-30 Impact factor: 7.914
Authors: Chelsea S Kidwell; Julio A Chalela; Jeffrey L Saver; Sidney Starkman; Michael D Hill; Andrew M Demchuk; John A Butman; Nicholas Patronas; Jeffry R Alger; Lawrence L Latour; Marie L Luby; Alison E Baird; Megan C Leary; Margaret Tremwel; Bruce Ovbiagele; Andre Fredieu; Shuichi Suzuki; J Pablo Villablanca; Stephen Davis; Billy Dunn; Jason W Todd; Mustapha A Ezzeddine; Joseph Haymore; John K Lynch; Lisa Davis; Steven Warach Journal: JAMA Date: 2004-10-20 Impact factor: 56.272
Authors: P A Barber; M D Hill; M Eliasziw; A M Demchuk; J H W Pexman; M E Hudon; A Tomanek; R Frayne; A M Buchan Journal: J Neurol Neurosurg Psychiatry Date: 2005-11 Impact factor: 10.154
Authors: Y Pierre Gobin; Sidney Starkman; Gary R Duckwiler; Thomas Grobelny; Chelsea S Kidwell; Reza Jahan; John Pile-Spellman; Alan Segal; Fernando Vinuela; Jeffrey L Saver Journal: Stroke Date: 2004-10-28 Impact factor: 7.914
Authors: Michael D Hill; Howard A Rowley; Felix Adler; Michael Eliasziw; Anthony Furlan; Randall T Higashida; Lawrence R Wechsler; Heidi C Roberts; William P Dillon; Nancy J Fischbein; Carolyn M Firszt; Gregory A Schulz; Alastair M Buchan Journal: Stroke Date: 2003-07-03 Impact factor: 7.914
Authors: Joseph V Guadagno; Elizabeth A Warburton; Franklin I Aigbirhio; Piotr Smielewski; Tim D Fryer; Sally Harding; Christopher J Price; Jonathan H Gillard; T Adrian Carpenter; Jean-Claude Baron Journal: J Cereb Blood Flow Metab Date: 2004-11 Impact factor: 6.200
Authors: Bijoy K Menon; Michael D Hill; Muneer Eesa; Jayesh Modi; Rohit Bhatia; John Wong; Mark E Hudon; Will Morrish; Andrew M Demchuk; Mayank Goyal Journal: Neuroradiology Date: 2010-06-08 Impact factor: 2.804
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: Michael D Hill; Andrew M Demchuk; Mayank Goyal; Tudor G Jovin; Lydia D Foster; Thomas A Tomsick; Rüdiger von Kummer; Sharon D Yeatts; Yuko Y Palesch; Joseph P Broderick Journal: Stroke Date: 2013-12-12 Impact factor: 7.914
Authors: Olvert A Berkhemer; Shervin Kamalian; R Gilberto González; Charles B L M Majoie; Albert J Yoo Journal: Cardiovasc Eng Technol Date: 2013-12-01 Impact factor: 2.495
Authors: V Mahajan; P T Minshew; J Khoury; P P Shu; M Muzaffar; T Abruzzo; J L Leach; T A Tomsick Journal: AJNR Am J Neuroradiol Date: 2008-03-20 Impact factor: 3.825
Authors: R I Aviv; J Mandelcorn; S Chakraborty; D Gladstone; S Malham; G Tomlinson; A J Fox; S Symons Journal: AJNR Am J Neuroradiol Date: 2007-10-05 Impact factor: 3.825